%0 Journal Article
%T The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
%A Shimazu Y
%A Kanda J
%A Onda Y
%A Fuchida SI
%A Ohta K
%A Shimura Y
%A Kosugi S
%A Yamamura R
%A Matsuda M
%A Hanamoto H
%A Adachi Y
%A Anzai N
%A Hotta M
%A Fukushima K
%A Yagi H
%A Yoshihara S
%A Tanaka Y
%A Takakuwa T
%A Tanaka H
%A Shibayama H
%A Uoshima N
%A Hosen N
%A Ito T
%A Shimazaki C
%A Matsumura I
%A Kuroda J
%A Takaori-Kondo A
%A Hino M
%J Cancer Immunol Immunother
%V 73
%N 7
%D 2024 May 17
%M 38758239
%F 6.63
%R 10.1007/s00262-024-03711-8
%X <B>BACKGROUND: </B>Isatuximab, an anti-CD38 antibody, has been widely used in treatments for patients with relapsed/refractory multiple myeloma (MM). Despite its high efficacy, not all patients achieve a lasting therapeutic response with isatuximab.<BR><B>OBJECTIVE: </B>We tried to identify biomarkers to predict the effectiveness of isatuximab by focusing on the host's immune status before treatment.<BR><B>METHODS: </B>We retrospectively analyzed the cases of 134 relapsed/refractory MM patients in the Kansai Myeloma Forum database who had received only a first isatuximab treatment.<BR><B>RESULTS: </B>Among the 134 patients, an isatuximab, pomalidomide and dexamethasone (Isa-PD) regimen, isatuximab, carfilzomib and dexamethasone (Isa-KD) regimen and isatuximab and/or dexamethasone (Isa-D) regimen were used in 112, 15 and 7 patients, respectively. The median age at treatment, number of prior treatment regimens, and progression-free survival (PFS) were 71, 6, and 6.54 months, respectively. Multivariate analysis showed that the PFS under the Isa-PD regimen was longer in patients with higher lymphocyte/monocyte ratio (LMR ≥ 4), fewer prior treatment regimens (< 6), and no use of prior daratumumab treatment. The OS under the Isa-PD regimen was longer in patients with higher white blood cell counts (WBC counts ≥ 3000/μL) and higher LMR. The PFS under the Isa-D regimen was longer in patients with fewer prior treatment regimens in univariate analysis, but no parameters were correlated with PFS/OS under the Isa-KD regimen.<BR><B>CONCLUSIONS: </B>We found that the patients with higher LMR (≥ 4) could obtain longer PFS and OS under the Isa-PD regimen. Other cohort studies of isatuximab treatment might be necessary to substantiate our results.